Loading organizations...
Helsinn is a global pharmaceutical company, headquartered in Lugano, Switzerland, founded in 1976 by Dr. Gabriele Braglia. This third-generation family-owned firm specializes in supportive care products, enhancing the well-being of patients with cancer and chronic diseases, particularly addressing side effects like chemotherapy-induced nausea and vomiting. Helsinn licenses, develops, manufactures, and commercializes its treatments through an integrated licensing model with long-standing partners, reaching patients in 90 countries worldwide. Originally a licensing business, it has strategically expanded into oncology therapeutics and broader chronic disease management, establishing itself as a fully integrated pharmaceutical firm. Key figures include CEO Riccardo Braglia and board member Paolo Guainazzi. The company also operates a USD 50 million Helsinn Investment Fund, reflecting its strong commitment to innovation and strategic growth, and was previously estimated to be a $350 million firm.
Key people at Helsinn.
Helsinn was founded in 1976 by Gabriele Braglia (Founder and Manager).
Helsinn was founded in 1976 by Gabriele Braglia (Founder and Manager).
Key people at Helsinn.
Helsinn has 3 tracked investments across 3 companies. The latest tracked deal is $11.1M Series B Extension in On Target Laboratories in March 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 14, 2018 | On Target Laboratories | $11.1M Series B Extension | Johnson & Johnson Innovation | Elevate Ventures, Aaron Davidson |
| Sep 1, 2017 | Amal Therapeutics | $10.0M Series B | Andreas Wallnoefer, Knut Elbers, Helsinn | Boehringer Ingelheim Venture Fund, High Tech Grunderfonds, Schroder Adveq, VI Partners |
| May 8, 2017 | Aadi Bioscience | $23.0M Series A | Jerry Xiao | Celgene, Decheng Capital, Star Summit Ventures, Mahendra Shah |
